Stereotaxis, Inc.

Sep 16, 2026

Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026

Stereotaxis will present its digital and robotic technologies at the Heart Rhythm Society's HRX conference from September 18-20, 2026. The company's CEO, David Fischel, will participate in a panel discussing autonomous technologies in electrophysiology labs. Synchrony, a recently FDA-cleared system, will be featured alongside SynX, a cloud-based connectivity platform.

Sep 3, 2026

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

The University of Szeged has successfully treated over 70 patients using the Genesis Robotic Magnetic Navigation system in its first month of operation. This program, the first of its kind in Hungary, aims to enhance the treatment of various arrhythmias with robotic precision. The Electrophysiology team has performed complex procedures, showcasing the potential of robotic technology in cardiac care.

Aug 11, 2026

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis reported strong second quarter results with robotic catheter revenue exceeding $1 million, marking a 270% increase. The company also made significant advancements with the first GenesisX robotic system sale and completed the acquisition of Robocath. Despite some declines in system revenue and increased operating losses, Stereotaxis anticipates continued growth and cash flow profitability by early 2027.

Jul 21, 2026

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

Stereotaxis, Inc. will release its financial results for the second quarter of 2026 on August 11, 2026. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss these results and any corporate developments. Stereotaxis is recognized for its innovations in surgical robotics for minimally invasive procedures.

Jul 20, 2026

University of Szeged Pioneers First Robotic Cardiology Program in Hungary

Stereotaxis has launched Hungary's first robotic cardiology program at the University of Szeged, utilizing the Genesis Robotic Magnetic Navigation System. This initiative aims to improve treatment for patients with complex cardiac arrhythmias. The program is expected to serve hundreds of patients annually and will also focus on training and research in robotic cardiology.

Jul 9, 2026

Stereotaxis Completes Acquisition of Robocath

Stereotaxis has completed its acquisition of Robocath, enhancing its capabilities in surgical robotics for endovascular interventions. The integration aims to combine their technologies to innovate robotic solutions for electrophysiology and interventional cardiology. Leaders from both companies express optimism about the strategic benefits and expanded market opportunities resulting from this merger.

May 13, 2026

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis reported its first quarter financial results for 2026, revealing a revenue decline to $6.3 million. The company achieved important FDA approvals and is optimistic about future growth, anticipating over $40 million in annual revenue. Despite challenges from transitioning away from Johnson & Johnson catheters, initial market adoption of new products is promising.

Apr 22, 2026

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis has announced the successful first use of its MAGiC catheter in the United States, which recently received FDA PMA approval. This innovative technology is designed for minimally invasive cardiac ablation procedures, particularly in patients with complex congenital heart disease. The first procedure was performed by Dr. Nathan McConkey, demonstrating the catheter's effectiveness in treating challenging anatomical conditions. The MAGiC catheter enhances precision and safety in cardiac interventions and is expected to considerably improve patient care.

Apr 21, 2026

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

Stereotaxis, a leader in surgical robotics for minimally invasive interventions, will report its financial results for the first quarter of 2026 on May 12, 2026. A conference call will be held at 4:30 p.m. EST that day to discuss these results and other corporate developments. The company's innovative technology has been instrumental in providing care for over 150,000 patients worldwide.

Apr 15, 2026

Stereotaxis Announces Definitive Agreement to Acquire Robocath

Stereotaxis (NYSE: STXS) has announced a definitive agreement to acquire Robocath, enhancing its capabilities in robotic solutions for endovascular procedures. This acquisition is aimed at integrating complementary technologies, facilitating the growth of advanced robotic platforms in interventional cardiology and neurointerventions. The deal, valued at $20 million upfront plus additional contingent payments, is expected to close in mid-2026 and to provide approximately $2 million in annual revenue in its first year. This strategic move is anticipated to position Stereotaxis favorably in large interventional markets with significant revenue potential.

Apr 6, 2026

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

Stereotaxis has announced the FDA clearance for its Synchrony system, designed to modernize interventional cath labs. This system features a 55-inch 4K ultra-high-definition display and offers benefits such as enhanced workflow, remote connectivity, and improved visualization for procedures. The company anticipates over $3 million in revenue from Synchrony systems, and emphasizes its foundational role in future innovations, including AI integration for enhanced clinical insights. The system aims to improve both patient care and operational efficiency in electrophysiology labs.

Mar 9, 2026

Stereotaxis Reports 2025 Full Year Financial Results

Stereotaxis, a leader in surgical robotics, reported a substantial 20% revenue growth for 2025, signaling positive advancements in their product pipeline. The company obtained regulatory approvals for its key innovations, namely the GenesisX robot and MAGiC ablation catheter. Despite modest early commercial contributions from these new products, Stereotaxis aims to achieve key milestones in 2026, including ramping up production and expanding market access. Their financial outlook remains optimistic with expectations of surpassing $40 million in annual revenue.

Feb 12, 2026

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

Stereotaxis (NYSE: STXS) announced it will release its financial results for the fourth quarter and full year of 2025 on March 9, 2026. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results and corporate developments. Stereotaxis is recognized for its innovative surgical robotics in minimally invasive procedures.

Feb 9, 2026

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Stereotaxis has launched a robotic electrophysiology program at Klinikum Fürth, marking the first of its kind in Germany. The Genesis Robotic Magnetic Navigation System will enhance treatment precision for patients with arrhythmias. Initial treatments have been successful, and the program aims to improve access to advanced cardiac care in the region.

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Stereotaxis has received FDA approval for its MAGiC Magnetic Interventional Ablation Catheter, representing a significant advancement in robotic cardiac ablation technology. This catheter aims to enhance treatment options for patients with complex heart rhythm disorders, particularly those who are underserved. With its robotically-navigated design, the catheter offers improved maneuverability and precision compared to traditional methods. Healthcare professionals express optimism regarding the positive implications of this innovation for better patient outcomes in electrophysiology.

Nov 24, 2025

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

Stereotaxis, a leader in surgical robotics, will participate in the Piper Sandler 37th Annual Healthcare Conference. CEO David Fischel is set to engage in a fireside discussion and hold one-on-one meetings on December 3rd, 2025. The company is currently experiencing significant regulatory progress and early commercial success.

Nov 11, 2025

▼ -14.7%on this news· ran to -26% by day 3

Stereotaxis Reports 2025 Third Quarter Financial Results

Stereotaxis reported its third quarter financial results for 2025, highlighting a revenue of $7.5 million, driven by the launch of new robotic systems and a strong performance from recurring revenue. The company experienced an increase in operating loss but expects revenue growth to exceed $9 million in Q4. Regulatory advancements and product launches are expected to bolster future performance.

Nov 10, 2025

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

Stereotaxis has received FDA 510(k) clearance for its GenesisX Robotic Magnetic Navigation System, which improves the accessibility of robotic technology in endovascular surgery. The system's compact design allows for easy installation in existing cath labs without major modifications. This marks a significant step in advancing robotic adoption in surgical procedures.

Oct 21, 2025

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

Stereotaxis, a leader in surgical robotics, announced it will report its third quarter financial results for 2025 on November 11, 2025. The financial results will be discussed during a conference call at 4:30 p.m. ET. Stereotaxis has gained recognition for its innovative solutions in minimally invasive endovascular procedures. This event highlights the company's ongoing commitment to improving patient care through advanced robotic technology.

Oct 15, 2025